Daily Briefs

• Key takeaways from the Medsphere acquisition: 1) post-acquisition, the company’s platform will span Medsphere’s hospital IT services along with CCLD’s Artificial Intelligence (AI) capabilities culminating in comprehensive/differentiated solutions offered within competitive cost structures 2) management plans to tap into Medsphere’s existing inpatient EHR and RCM relationships across small- and mid-sized hospitals, aligning with ongoing initiatives to further expand CCLD’s footprint to drive sustainable growth 3) we are raising our Adjusted EPS estimates after layering in incremental revenue related to the transaction and 4) expected Medsphere revenue of approximately $16.5 million on an annualized basis equates to 15% of the midpoint of management’s prior 2025 revenue guidance range of $111 million to $114 million.

• According to the disclosure in 25H1 report, CNPGC will still fulfill its commitment to resolving the issue of horizontal competition.So, the merger of China TCM and Taiji remains an option.
• Although Taiji’s performance declined sharply in 25H1, the announcement of the stock repurchase indicates that the Company remains optimistic about its prospects and tries to protect the interests of shareholders.
• There’s high possibility of performance recovery in 2026.In 2027, Taiji would enter a new round of growth. So, 2025 is the low point, which provides a good opportunity to buy.

• CSPC Pharmaceutical Group (1093 HK) 1H25 revenue dropped 18.5% YoY as finished drugs witnessed decrease on VBP and NRDL inclusion. Bulk products and license fees compensated to an extent.
• More license and collaboration in relation to the development, manufacturing and commercialization of certain products of the company awaited in 2H25 and augurs well in terms of future revenue visibility.
• CSPC Pharmaceutical aims to expand into the high-end market to achieve competitive differentiation and thereby command higher prices.

• Eli Lilly and Company’s second-quarter 2025 financial results represent a blend of remarkable achievements and strategic foresight, coupled with challenges typical of the pharmaceutical industry.
• The company reported a robust 38% increase in revenue compared to Q2 2024, driven primarily by key products like Mounjaro, Zepbound, and Verzenio.
• This outcome highlights the strong demand for its therapies across major therapeutic areas, especially in cardiometabolic health and oncology.

• The second quarter results for Insulet Corporation, a leader in insulin management systems, indicate a robust performance with significant development across key financial metrics.
• The company reported a notable 31% revenue growth year-over-year, reaching $649 million, surpassing the $600 million benchmark for the first time.
• This impressive growth is attributed to increasing consumer adoption across various segments including U.S. Type 1, Type 2, and international markets, largely driven by the Omnipod 5’s technology and its clinical benefits.

• Natera reported a promising financial and operational performance for Q2 2025.
• The company’s revenue reached $547 million, representing a 32% year-on-year increase, which, when excluding revenue adjustments, marked an organic growth of 34%.
• This performance was bolstered by substantial demand for its oncology products, particularly Signatera, which saw a record of 189,000 processed tests during the quarter.

Oryzon Genomics has announced that the European Medicines Agency (EMA) has provided regulatory clearance for a Phase Ib trial of iadademstat in sickle cell disease. The Phase Ib study (named RESTORE) is expected to enrol 40 adult patients with the condition, and will be based across multiple sites in Spain. The trial is primarily designed to assess the safety and tolerability of the drug candidate, as well as to determine the recommended Phase II dose, with secondary objectives focused on measurements of foetal haemoglobin. While we acknowledge that this is an early-stage programme, we believe it represents a key milestone for Oryzon, since it will be the first investigation of iadademstat in a non-malignant haematological indication.